New epilepsy drug shows promise in final stage trial
Disease control
Completed
This Phase 3 trial tested a drug called XEN1101 (azetukalner) in 380 adults with focal-onset seizures that were not well-controlled by other medications. Participants took either XEN1101 or a placebo alongside their usual seizure drugs. The study measured whether XEN1101 reduced …
Phase: PHASE3 • Sponsor: Xenon Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC